Try C, Messikh R, Elkhyat A, Aubin F, Humbert R P
Service de Dermatologie, Hôpital de Besançon, France.
Rev Med Liege. 2012 Oct;67(10):520-6.
Oxybutynin is being increasingly being prescribed in the treatment of hyperhidrosis but currently, there is no precise dosage for this treatment. Nine patients were treated for primary hyperhidrosis resistant to conventional therapies with oxybutynin between January to May 2010. The treatment was progressively increased at 7.5 mg per day. Oxybutynin efficacy was evaluated by iodine starch test and biometrological measurements at 2 and 4 weeks of treatment. Hyperhidrosis Disease Severity Scale (HDSS) and Dermatology Life Quality Index (DLQI) were obtained for each patient. The means of HDSS and DLQI were respectively 3.2 +/- 0.7 and 17.0 +/- 5.1 before treatment and were 1.8 +/- 0.4 and 4.6 +/- 4.4 at 4 weeks of treatment. Oxybutynin at 7.5 mg per day significantly decreased intensity and area of sweat for palms but not for soles. Trans Epidermal Water Loss, conductance, pH and Skin temperature were modified with treatment. Oxybutynin at 7.5 mg per day has improved patient's quality of life. Efficiency of oxybutynin in primary palmar hyperhidrosis was proved by biometrological measurements and iodine starch test.
奥昔布宁越来越多地被用于治疗多汗症,但目前对于这种治疗方法尚无精确的剂量。2010年1月至5月期间,9例对传统疗法耐药的原发性多汗症患者接受了奥昔布宁治疗。治疗剂量以每天7.5毫克的幅度逐步增加。在治疗2周和4周时,通过碘淀粉试验和生物计量学测量来评估奥昔布宁的疗效。为每位患者获取多汗症疾病严重程度量表(HDSS)和皮肤病生活质量指数(DLQI)。治疗前HDSS和DLQI的平均值分别为3.2±0.7和17.0±5.1,治疗4周时分别为1.8±0.4和4.6±4.4。每天7.5毫克的奥昔布宁显著降低了手掌出汗的强度和面积,但对脚底无效。治疗改变了经表皮水分流失、电导、pH值和皮肤温度。每天7.5毫克的奥昔布宁改善了患者的生活质量。生物计量学测量和碘淀粉试验证明了奥昔布宁对原发性掌跖多汗症的疗效。